Status:
UNKNOWN
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
Lead Sponsor:
Stephen E. Goldstone
Conditions:
HSIL, High Grade Squamous Intraepithelial Lesions
Anal Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this research is to assess the safety and effectiveness of circumferential radiofrequency ablation (RFA) to the anal canal using the BarrxTM Ablation System to destroy anal high-grade s...
Eligibility Criteria
Inclusion
- Age 18-75 years
- HRA 2 to 8 weeks prior to the 0 month RFA visit yielding one or more flat, non- condylomatous biopsy-proven HSILs that are
- Located entirely within the eligible treatment zone AND
- Contiguous with the squamocolumnar junction
- Eligible treatment zone (ETZ) is defined as
- 3 cm above the dentate line to the anocutaneous line AND
- Full anorectal circumference
- If female of child-bearing age, negative pregnancy test within 8 weeks of the 0 month RFA visit and declared intent to remain on birth control throughout the trial, or declaration of infertility defined as subject report of status as post-menopausal or surgically sterile (status post hysterectomy or tubal ligation).
- If HIV positive
- HIV positive on antiretroviral therapy for at least 3 months with laboratory blood work within 12 weeks prior to the 0 month visit demonstrating viral load \< 50
- CD4 count ≥ 250/mm3
- ANC \> 750/mm3
- Platelet count ≥ 75,000/mm3
- Hemoglobin ≥ 9.0 g/dl
Exclusion
- Any biopsy-proven HSIL partially outside of the ETZ (for example, an HSIL lesion with extension to the perianal skin)
- Any condylomas in the eligible treatment zone \> 1/2 cm diameter
- Any anal or rectal pathology requiring treatment including ulcer, fistula, fissure, or proctitis
- Any anal stricture or stenosis in patient history or upon examination.
- Symptomatic scarring in anal canal (i.e. not pliable, hyperkeratosis)
- History of or present anal or rectal cancer
- History of pelvic radiation therapy
- History of HPV vaccination or plans to initiate HPV vaccination during the trial
- History of ablation or resection therapy within the ETZ within 3 months prior to the 0 month RFA visit (other than cauterization or excision of condylomata)
- History of topical therapy (e.g. Imiquimod, 5-FU, Trichloroacetic acid) within the
- ETZ within 3 months prior to the 0 month RFA visit
- Hemorrhoids \> grade III
- Fecal incontinence
- Concurrent disease requiring systemic immunosuppression therapy
- Concurrent malignancy requiring systemic therapy
- Life expectancy \< 2 years
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03302858
Start Date
October 1 2017
End Date
October 1 2020
Last Update
October 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laser Surgery Care
New York, New York, United States, 10011